checkAd

     673  0 Kommentare HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization - Seite 3

    Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

    For further information, please contact:

    Lesen Sie auch

    Investors & Media
    Michael Kaiser, Investor Relations
    michael.kaiser@hookipapharma.com
    + 1 (917) 984 7537        


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization - Seite 3 NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of …